Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET

Company Participants

Joshua Higa - Vice President, Investor Relations
Emil Kakkis - Chief Executive Officer & President
Erik Harris - Chief Commercial Officer
Howard Horn - Chief Financial Officer
Eric Crombez - Chief Medical Officer

Conference Call Participants

Gena Wang - Barclays
Salveen Richter - Goldman Sachs
Dae Gon Ha - Stifel
Tazeen Ahmad - Bank of America
Kristen Kluska - Cantor Fitzgerald
Joon Lee - Truist
Maury Raycroft - Jefferies
Will Soghikian - Leerink Partners
Yaron Werber - TD Cowen
Michael Riad - Morgan Stanley
Jack Allen - Baird
Lisa Walter - RBC

Operator

Good afternoon, and welcome to the Ultragenyx Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have opportunity to ask questions during the question-and-answer portion of the call.

[Audio Gap] Vice President of Investor Relations. Please go ahead.

Joshua Higa

Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President, Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer.

I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.

I'll now turn the call over to Emil.

Emil Kakkis

Thanks Josh, and good afternoon, everyone. We've had an incredible first half of the year and look forward to sharing more with you today. On the commercial front, our strong revenue performance puts us on the trajectory to outperform our prior projections and so we're raising our total revenue guidance range. We're happy with what this means for access to our drugs globally and Eric and Howard can share more on the revenue details.

Within our clinical pipeline we have meaningfully advanced our late-stage programs through multiple positive data readouts and successful and critically important regulatory interactions.

On the data front in addition to the positive results we shared earlier this year on both UX-111 in Sanfilippo syndrome and GTX-102 in Angelman syndrome, we recently announced positive Phase III results from the DTX401 gene therapy for the treatment of patients with glycosidase Type 1a and additional long-term positive Phase II results from the UX143 antibody for the treatment of patients with Osteogenesis Imperfecta.